ML19339E716
| ML19339E716 | |
| Person / Time | |
|---|---|
| Site: | SHINE Medical Technologies |
| Issue date: | 12/04/2019 |
| From: | SHINE Medical Technologies |
| To: | Office of Nuclear Reactor Regulation |
| Shared Package | |
| ML19339E714 | List: |
| References | |
| 2019-SMT-0135 | |
| Download: ML19339E716 (43) | |
Text
42 pages follow ENCLOSURE 2 SHINE MEDICAL TECHNOLOGIES, LLC MEETING SLIDES FOR THE DECEMBER 4 AND 5, 2019 PUBLIC MEETING BETWEEN SHINE MEDICAL TECHNOLOGIES, LLC AND THE NRC SHINE OVERVIEW PUBLIC VERSION
SHINE Overview Tracy Radel, Director of Process Engineering
2 SHINE Medical Technologies l SHINE High Level Overview 1
2 3
4 5
6 LEU is dissolved to form the liquid target Accelerator fires ion beam into tritium gas target chamber Ions from accelerator beam undergo fusion with gas target, freeing neutrons into target solution tank Uranium undergoes fission in target solution tank, producing Mo-99 and other isotopes Mo-99 is captured from the solution via an extraction column The LEU solution is returned to the target solution tank 1
2 3
4 5
6
SHINE Medical Technologies l 3 Process Overview
- 1. Periodic solution preparation from LEU
- 2. Solution chemistry check and staging
- 3. Irradiation for 5.5 days
- 4. Extraction, purification, QC & packaging
- 5. Waste handling
SHINE Medical Technologies l 4 Technological Approach Small systems: 125 kW, hundreds of times less power than isotope production reactors being used
Low source termhelps ensure safety of public and workforce
Decay heat per system < 1 kW within 5 hours5.787037e-5 days <br />0.00139 hours <br />8.267196e-6 weeks <br />1.9025e-6 months <br />
Minimizes waste nuclide generation compared to reactors Low enriched uranium (LEU) reusable target
Reduces waste
Product compatible with current supply chain
Eliminates need for HEU Driven by low-energy electrostatic accelerator
Fission essentially terminate shortly after driver turned off Multiple units and trains provide operational scalability and flexibility
SHINE Medical Technologies l 5 Low decay heat, low pressure, low temperature system
Minimal stored energy Independent units limit common cause failures Operator actions are not required for safe response to an accident In the event of an upset condition:
TSV reactivity protection system (TRPS) initiates trip of system
Two completely independent safety-related TSV dump valves open
Target solution gravity drains to the TSV dump tank (criticality safe at all uranium concentrations)
Hydrogen concentration maintained below lower flammability limit (LFL) by off-gas system blowers Following UPS battery run time, entire plant is passively safe
90 days without cooling: pool temperature rise is not more than 13°F
Nitrogen purge system for hydrogen control Safety Philosophy
SHINE Medical Technologies l 6 Facility Layout - General Arrangement Security-Related Information - Withheld Under 10 CFR 2.390(d)
SHINE Medical Technologies l 7 Facility Layout - Elevation and Section Views Security-Related Information - Withheld Under 10 CFR 2.390(d)
SHINE Medical Technologies l 8 Major Processes Target solution preparation Irradiation
Subcritical assembly
Neutron driver
Off-gas system Extraction Purification Waste handling Target solution recycle
SHINE Medical Technologies l 9 Facility designed to receive either uranium metal or uranium oxide Uranium metal would be oxidized in a furnace prior to dissolution Dissolution Process
U3O8 is dissolved in sulfuric acid and peroxide
Mechanically agitated during process
Heated to destroy peroxide, producing clear yellow uranyl sulfate solution
[ ]PROP/ECI catalyst added for peroxide destruction during irradiation Adjusted to correct uranium concentration and pH using water and sulfuric acid Target Solution Preparation Proprietary Information - Withheld from public disclosure under 10 CFR 2.390(a)(4)
Export Controlled Information - Withheld from public disclosure under 10 CFR 2.390(a)(3)
SHINE Medical Technologies l10 Major Processes Target solution preparation Irradiation
Subcritical assembly
Neutron driver
Off-gas system Extraction Purification Waste handling Solution recycle
SHINE Medical Technologies l11 Hybrid fusion-fission device
Accelerator generates fusion neutrons from D-T reaction
Subcritical assembly takes fusion neutrons, slows them down, and multiplies them through fission reactions Process
Fast neutrons created in center of assembly (neutron spark plug)
Neutrons pass through natural uranium multiplier
Multiplied neutrons pass into uranium solution in TSV, where they are absorbed by uranium and cause fission
Transfer solution to the processing facility for isotope removal Subcritical Assembly Overview Proprietary Information - Withheld from public disclosure under 10 CFR 2.390(a)(4)
Export Controlled Information - Withheld from public disclosure under 10 CFR 2.390(a)(3)
PROP/ECI
SHINE Medical Technologies l12 Key parameters:
Pressure: Below atmospheric
Temperature: < 212°F
Target solution: Uranyl sulfate
Reactivity: Subcritical
Stability: Negative temperature and void coefficients of reactivity
Cooling: No active cooling required after shutdown
Shutdown: Gravity drain to geometrically favorable tank Low Energy, Inherently-Safe System PROP/ECI Proprietary Information - Withheld from public disclosure under 10 CFR 2.390(a)(4)
Export Controlled Information - Withheld from public disclosure under 10 CFR 2.390(a)(3)
SHINE Medical Technologies l13 Key components:
Neutron driver target chamber
Neutron multiplier
Target solution vessel (TSV)
Subcritical assembly support structure
Subcritical multiplication source
TSV dump valves (not shown)
TSV dump tank Subcritical Assembly Proprietary Information - Withheld from public disclosure under 10 CFR 2.390(a)(4)
Export Controlled Information - Withheld from public disclosure under 10 CFR 2.390(a)(3)
PROP/ECI
SHINE Medical Technologies l14 Mode 0 - Solution Removed: No target solution in the SCAS Mode 1 - Startup: Filling the TSV Mode 2 - Irradiation: Operating mode (neutron driver active)
Mode 3 - Post-Irradiation: TSV dump valves open Mode 4 - Transfer to RPF: Dump tank drain valves open to permit solution transfer Operational Modes
SHINE Medical Technologies l15 Startup similar to a reactor, except the endpoint is different
Operators plot 1/M curve with solution volume
Operators stop fill when 5% by volume below predicted critical volume Aspect ratio of the assembly results in high multiplication while still maintaining large volume margin to critical Driven further from critical during operation Keff values:
Nominal core: [ ]PROP/ECI
Limiting core: [ ]PROP/ECI Subcritical Assembly Proprietary Information - Withheld from public disclosure under 10 CFR 2.390(a)(4)
Export Controlled Information - Withheld from public disclosure under 10 CFR 2.390(a)(3)
SHINE Medical Technologies l16 Nuclear
MCNP5 v1.60 with ENDF/B-VII.1 and ENDF/B-VII.0 (for S(,)) nuclear data libraries used
Validations performed to quantify uncertainties in temperature coefficients, void coefficients, and solution worth
ORIGEN-S in SCALE 6.1 package used to generate radionuclide inventories following irradiation and decay Thermal hydraulics
Correlation-based methodology used for safety-related calculations
Based on experimental data applicable to the SHINE system Transient Analysis
TRIAD code developed in conjunction with Los Alamos National Laboratory
Calculates combined effects of temperature, void, and reactivity feedback Subcritical Assembly Analysis Overview
SHINE Medical Technologies l17
Source Strength and Detector Placement
Startup Curves and Limiting Core Configurations
Nominal and Limiting Core Configuration Characteristics
Neutron Lifetime and Effective Neutron Fraction
Coefficients of Reactivity
Neutron Flux, Fluence, and Power Distributions
Radiolysis Rates at Steady State and After Shutdown in the Target Solution Vessel
Extent and Effects of Nonuniformities on Operation
Neutron Multiplier Nuclear Design Parameters over Lifetime
Effects of Uranium Burnup
Bounding Fission Product Inventories and Source Terms
Nominal Fission Product Inventories and Source Terms
Neutron Multiplier Radionuclide Inventory Key Nuclear Analysis Calculations Proprietary Information - Withheld from public disclosure under 10 CFR 2.390(a)(4)
Export Controlled Information - Withheld from public disclosure under 10 CFR 2.390(a)(3)
PROP/ECI
SHINE Medical Technologies l18 Point Reactor Kinetics
Target Solution Vessel Fill System Design
Limiting Credible Fill Analysis TRIAD
Target Solution Vessel Transient Analysis
Target Solution Vessel Transient Stability with Respect to Bubble Velocity Transient Analysis Calculations PROP/ECI Proprietary Information - Withheld from public disclosure under 10 CFR 2.390(a)(4)
Export Controlled Information - Withheld from public disclosure under 10 CFR 2.390(a)(3)
SHINE Medical Technologies l19
Target Solution Vessel Cooling
Target Solution Vessel (TSV) Dump Tank Thermal Hydraulics
Target Solution Vessel (TSV) Thermal Hydraulics
Target Solution Vessel (TSV) Cooldown
Neutron Multiplier Nuclear Design Parameters over Lifetime Thermal Hydraulics Calculations PROP/ECI Proprietary Information - Withheld from public disclosure under 10 CFR 2.390(a)(4)
Export Controlled Information - Withheld from public disclosure under 10 CFR 2.390(a)(3)
SHINE Medical Technologies l20
Neutron driver is hydrogen particle accelerator
Supplied by Phoenix
300 kV constant voltage (static)
Accelerates deuterium ions into a tritium gas target
Neutron production rate: [ ]PROP/ECI to 1.5E+14
Neutron source to drive the subcritical chain reactions
Operation is not safety function
Turning off accelerator is a safety function
Safety-related breakers isolate power feed to accelerator high voltage power supply Neutron Driver Proprietary Information - Withheld from public disclosure under 10 CFR 2.390(a)(4)
Export Controlled Information - Withheld from public disclosure under 10 CFR 2.390(a)(3)
Security-Related Information - Withheld Under 10 CFR 2.390(d)
PROP/ECI/
SHINE Medical Technologies l21 The TOGS sweeps the TSV and TSV dump tank headspaces to maintain bulk hydrogen within the primary system boundary below the lower flammability limit (LFL)
Sweep gas passed over catalytic recombiner beds to form water vapor
Water vapor generated by the TSV and the recombiner beds is condensed and returned to the TSV The TOGS absorbs iodine in the sweep gas to limit the dose consequences in the event of a leak TSV Off-Gas System (TOGS)
Proprietary Information - Withheld from public disclosure under 10 CFR 2.390(a)(4)
Export Controlled Information - Withheld from public disclosure under 10 CFR 2.390(a)(3)
PROP/ECI
SHINE Medical Technologies l22 TOGS general parameters
Sweep gas flowrate: [ ]PROP/ECI
Design nominal hydrogen concentration: 2%
Condensate return rate: < 2.7 lbm/hr
Recombiner materials: [
]PROP/ECI Safety-related functions to ensure hydrogen concentrations remain acceptable Operates on UPSS power for 5 minutes following loss of off-site power to recombine decay hydrogen TSV Off-Gas System (TOGS)
Proprietary Information - Withheld from public disclosure under 10 CFR 2.390(a)(4)
Export Controlled Information - Withheld from public disclosure under 10 CFR 2.390(a)(3)
PROP/ECI
SHINE Medical Technologies l23 Major Processes Target solution preparation Irradiation
Subcritical assembly
Neutron driver
Off-gas system Extraction Purification Waste handling Target solution recycle
SHINE Medical Technologies l24 Target solution transferred from IU cell to hot cells via vacuum lift system Mo-99 separated from target solution by extraction column Mo-99 eluted from extraction column and pH adjusted with nitric acid
[
]PROP/ECI
[
]PROP/ECI Mo-99 solution concentrated by evaporation and transferred to purification Overview of Mo-99 Separation Process Proprietary Information - Withheld from public disclosure under 10 CFR 2.390(a)(4)
Export Controlled Information - Withheld from public disclosure under 10 CFR 2.390(a)(3)
PROP/ECI
SHINE Medical Technologies l25 Purification via the Low Enriched Uranium (LEU) Modified Cintichem Process
Developed by Argonne National Laboratory for the Department of Energy Cintichem is a long-established process
Used at the Cintichem facility in Tuxedo, NY until 1989 Process performed with manipulators in hot cell
Precipitation and filtration of contaminants
Complexation of molybdenum
Adsorption and filtration of contaminants on charcoal columns Overview of Mo-99 Purification Process
SHINE Medical Technologies l26
The hot cell (supercell) consists of ten hot cells:
Each cell type performs specific functions
Redundancy is included to handle the 8 irradiation cells and provide flexibility in operations Supercell
- 1. Process vessel vent system (PVVS)
- 2. Extraction #1
- 3. Purification #1
- 4. Packaging #1
- 5. Purification #2
- 6. Extraction #2
- 7. Extraction #3
- 8. Purification #3
- 9. Packaging #2 10.Iodine and xenon Proprietary Information - Withheld from public disclosure under 10 CFR 2.390(a)(4)
Export Controlled Information - Withheld from public disclosure under 10 CFR 2.390(a)(3)
PROP/ECI
SHINE Medical Technologies l27 Supercell Design Safety function to confine radioisotopes upon release
Confinement limits release to stack and to Radioisotope Production Facility (RPF) area Provides biological shielding for workers Criticality safety controls incorporated Proprietary Information - Withheld from public disclosure under 10 CFR 2.390(a)(4)
Export Controlled Information - Withheld from public disclosure under 10 CFR 2.390(a)(3)
PROP/ECI
SHINE Medical Technologies l28 Major Processes Target solution preparation Irradiation
Subcritical assembly
Neutron driver
Off-gas system Extraction Purification Waste handling Target solution recycle
SHINE Medical Technologies l29 Waste Stream Overview
Three types of radioactive waste:
As generated solid radioactive waste, including spent adsorption columns
Solidified radioactive waste
Gaseous wastes Liquid waste is collected in favorable and non-favorable geometry tanks, depending on liquid waste stream
Size and configuration of liquid waste tanks provide for operational flexibility
Liquid waste streams are analyzed and blended to allow for solidification and acceptance at a licensed burial facility
Waste streams are solidified in a shielded enclosure maintained at a slight negative pressure compared to the surrounding RPF Waste Handling
SHINE Medical Technologies l30 Radioactive Liquid Waste Storage System Security-Related Information - Withheld Under 10 CFR 2.390(d)
SHINE Medical Technologies l31 Radioactive Liquid Waste Immobilization System Receives liquid wastes from the liquid waste blending tank Solidifies waste with an immobilization agent in accordance with the process control program Drums are cured and transported to on-site staging building, prior to offsite shipment Radioactive Liquid Waste Immobilization Shielded Enclosure
SHINE Medical Technologies l32 Gaseous Waste Handling Gaseous wastes are processed by the process vessel vent system (PVVS)
PVVS contains carbon guard bed to remove iodine Gases then passed through carbon delay beds which hold up krypton and xenon Sized for minimum delay of 40 days for xenon Safety function to reduce radiological dose to the public Carbon Delay Beds
SHINE Medical Technologies l33 Major Processes Target solution preparation Irradiation
Subcritical assembly
Neutron driver
Off-gas system Extraction Purification Waste handling Target solution recycle
SHINE Medical Technologies l34 Target solution will be reused cycle-to-cycle
Limiting lifetime set by burnup of safety-basis source term
[
]PROP/ECI
[
]PROP/ECI Small process losses expected between cycles Solution will be adjusted periodically to compensate for these losses Target Solution Recycle Proprietary Information - Withheld from public disclosure under 10 CFR 2.390(a)(4)
Export Controlled Information - Withheld from public disclosure under 10 CFR 2.390(a)(3)
SHINE Medical Technologies l35 Three ventilation systems in the radiologically controlled area (RCA) are used to maintain the temperature and humidity of the RCA and to progress air from areas of least potential for contamination to areas with the most potential for contamination
Radiological ventilation zone 3 (RVZ3)
Services areas of entry/egress for RCA
Radiological ventilation zone 2 (RVZ2)
Services normally occupied areas within the RCA
Radiological ventilation zone 1 (RVZ1)
Services areas with highest potential for contamination
Two subsystems interface with the primary confinement boundary
RVZ1 exhaust subsystem (RVZ1e): low flowrate pulled from the primary confinement through the PCLS expansion tank to limit hydrogen buildup due to radiolysis in the pool and maintain the IU and TOGS cells at a slightly negative pressure
RVZ1 recirculation subsystem (RVZ1r): closed loop that circulates and cools the air within the IU and TOGS cells Radiological Ventilation Zones
SHINE Medical Technologies l36 Commitments to codes and standards were made within chapters as necessary to meet regulatory requirements Summary not provided in Section 3.1 in effort to minimize duplication Additional codes and standards are used throughout design documents to meet design requirements Examples:
Target solution vessel: American Society of Mechanical Engineers (ASME) Boiler and Pressure Vessel Code (BPVC) - Rules for Construction of Pressure Vessels,Section VIII, Division 1, 2010
Primary system boundary piping: Code for Pressure Piping, ASME B31.3-2012
Neutron flux detectors: IEEE Standard 384-2008, IEEE Standard Criteria for Independence of Class 1E Equipment and Circuits, invoked for separation of safety-related and nonsafety-related raceways Approach to Commitments to Codes and Standards
SHINE Medical Technologies l37 Like the Preliminary Safety Evaluation Report (PSAR), the development of the Final Safety Analysis Report (FSAR) followed the format and content guidance of NUREG-1537 and the Interim Staff Guidance (ISG) augmenting NUREG-1537
Development of Chapter 7 (Instrumentation and Control Systems) followed the format and content guidance of the draft Chapter 7 ISG augmenting NUREG-1537 Chapters containing system descriptions are split between IF-located systems (e.g.,
Chapter 9a2) and RPF-located systems (e.g., Chapter 9b), consistent with the format guidance provided in the ISG augmenting NUREG-1537
Systems common to both the IF and the RPF are described in the IF portion of the chapter, and the corresponding RPF portion provides a statement related to the commonality of the system and a reference to the appropriate IF portion of the chapter
Examples include Section 5b, which identifies SHINE cooling systems as common to the IF and the RPF, with reference to Section 5a2; and Section 9b.1, which identifies SHINE heating, ventilation, and air conditioning (HVAC) systems as common to the IF and RPF, with reference to Section 9a2.1 Strategy for FSAR Organization
Technical Specification Development
SHINE Medical Technologies l39 Technical specifications for the SHINE facility required by 10 CFR 50.36 Formatting of the SHINE technical specifications follows the guidance provided in NUREG-1537, as modified by the Final Interim Staff Guidance (ISG) Augmenting NUREG-1537, and ANSI/ANS 15.1-2007, with the following exception:
ANSI/ANS 15.1-2007, Section 3.0 (Limiting condition of operation) and Section 4.0 (Surveillance Requirements), were combined into a single SHINE Section 3.0, to more clearly relate each Surveillance Requirement to the applicable Limiting Condition of Operation SHINE Technical Specifications
SHINE Medical Technologies l40 Safety Limits
Selected to comply with 10 CFR 50.36(c)
Meet the intent of guidance provided by NUREG-1537 and the ISG augmenting NUREG-1537
Final selection limited to those variables directly related to protecting physical barriers
Limits on variables that indirectly protect barriers are incorporated into LCOs Limiting Conditions of Operation (LCO)
Derived from controls identified in the Integrated Safety Analysis (ISA) Summary
Based on assumptions used in, or limits derived from, safety analysis calculations Surveillance Requirements (SR)
SRs identified for each LCO
Selected surveillances and frequencies based on guidance from ANSI/ANS 15.1-2007 whenever parallels existed
Industry experience, for example other NPUF technical specifications, or engineering judgement used where parallels did not exist Development Strategy
SHINE Medical Technologies l41 LCO Applicability
Applicability statements were defined for each LCO individually to clearly define when equipment is required to be Operable
SHINE processes follow a batch sequence, where not all LCOs are applicable to all conditions or modes
Applicability of LCOs intended to clarify when maintenance and testing is permissible (i.e., when the function is not required)
LCO Actions
Actions to be taken when the LCO is not met were defined for each LCO
Definition of specific actions is necessary because generic actions (e.g., to shut down an IU) are not applicable to all processes within the facility
Provides clarity to operators on required actions Development Strategy
SHINE Medical Technologies l42 Design Features
Selected based on guidance from ANSI/ANS 15.1-2007, and
Based on safety-related controls identified in the ISA that did not clearly map to an LCO (e.g.,
passive engineered controls)
Administrative Controls
Section 5.5, Programs, is based on guidance from ANSI/ANS 15.1-2007 and includes the following elements identified in the ISA Summary:
Programmatic administrative controls
Select safety-related controls (e.g., specific administrative controls) that did not fit as LCOs or design features
Select reliability management measures that did not fit as SRs
Other sections (e.g., Organization, Review and Audit, Radiation Safety, Procedures, Required Actions, Reports, and Records) are based on guidance from ANSI/ANS 15.1-2007 with modifications for applicability to SHINE Development Strategy